The First Discovery of a Single Digit Nanomolar Small Molecule Blocker of a Protein-protein Interaction Target

Video   Jul 03, 2015

 



About the Speaker
Dr. Nils Hansen is the CEO and founder of Vipergen ApS. He is the principal inventor of the enabling YoctoReactor® and Binder Trap Enrichment® drug discovery technology platforms. He previously worked for Praecis Pharmaceuticals Inc., (Waltham, MA, USA) and Symphogen A/S, (Copenhagen, Denmark). Dr. Hansen earned his Ph.D. in immunology from the University of Copenhagen, Denmark in 2000 and his M.Sc. in Chemistry and Biotechnology from the University of Aarhus, Denmark in 1996.Abstract
Effective small molecule PPI blocker discovery using high fidelity DNA-encoded libraries and a low-noise homogeneous screening assay. The screen employs a unique principle of trapping small molecule binders together with the protein target in miniscule droplets.

 
 
 
 

Recommended Videos

The All New Affinity ITC - Perfected ITC Automation

Video

While others have attempted ITC automation, leading to bent syringes and imperfect data, TA Instruments has perfected it with the all new Affinity ITC!

WATCH NOW

MicroCal PEAQ-ITC: The gold standard for measuring binding affinities

Video

This video describes the 4 main reasons why MicroCal PEAQ-ITC is the ideal instrument for measuring binding affinities.

WATCH NOW

Professor Anita Maguire Tells Us About How and Why Her Lab Performs Chemistry in Flow

Video

Lab Tube Meets Prof. Anita Macguire at Flow Chem Europe 2017. Anita describes how and why her lab performs their organic chemistry reactions in Flow.

WATCH NOW

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE